

H · S · G

HUNTINGTON · STUDY · GROUP

Contact: Leslie Briner
(585) 273-4147

Leslie.Briner@CTCC.Rochester.Edu

October 10, 2006

FOR IMMEDIATE RELEASE

HSG to Conduct Research Study in Adults with Mild to Moderate Huntington's Disease

The Huntington Study Group (HSG) will be conducting a clinical study "A Multicenter, Phase 1-2A, Open-Label, Dosage-Escalation and Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects with Huntington's Disease" (**DIMOND**) with the research medication – **Dimebon** – in patients who have mild to moderate Huntington's disease (HD). The HSG is a worldwide, not-for-profit group of physicians and other clinical researchers who are experienced in the care of Huntington's disease patients and dedicated to clinical research of Huntington's disease. The study is sponsored by Medivation, Inc. with headquarters in San Francisco, CA.

Huntington's disease (HD) is an inherited disease of the brain that usually begins between the ages of 30 to 50, and includes motor, cognitive and behavioral signs and symptoms. While there are medications to help relieve some of the disease symptoms, there is no known treatment to slow the progression of HD, which affects about 30,000 people in North America.

Dimebon is a research (experimental) medication that is thought to improve learning and memory. This current study is designed to determine how safe and tolerable Dimebon is in people with HD after short term exposure. Also the study will assess whether or not there is an effect of Dimebon on HD symptoms, including cognitive (thinking abilities), motor (movement), and overall functioning.

There is no cost to participate in the study. Individuals with mild to moderate Huntington's disease are eligible to participate in this study.